CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Preclinical antibiotic pipeline gets a pick-me-up. Nat Rev Drug Discov 16, 741–742 (2017). https://doi.org/10.1038/nrd.2017.213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.213
This article is cited by
-
Hürden und Aussichten neuer antimikrobieller Konzepte in Forschung und Entwicklung
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2018)